BRPI0817927A2 - Comprimidos orodispersiveis - Google Patents

Comprimidos orodispersiveis

Info

Publication number
BRPI0817927A2
BRPI0817927A2 BRPI0817927-1A BRPI0817927A BRPI0817927A2 BR PI0817927 A2 BRPI0817927 A2 BR PI0817927A2 BR PI0817927 A BRPI0817927 A BR PI0817927A BR PI0817927 A2 BRPI0817927 A2 BR PI0817927A2
Authority
BR
Brazil
Prior art keywords
orodispersible
pills
orodispersible pills
Prior art date
Application number
BRPI0817927-1A
Other languages
English (en)
Inventor
Carmen Úbeda Pérez
Ignacio Diez Martin
Pablo Pablo Alba
Original Assignee
Lesvi Laboratorios Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lesvi Laboratorios Sl filed Critical Lesvi Laboratorios Sl
Publication of BRPI0817927A2 publication Critical patent/BRPI0817927A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
BRPI0817927-1A 2007-10-01 2008-09-30 Comprimidos orodispersiveis BRPI0817927A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07380265 2007-10-01
US97716607P 2007-10-03 2007-10-03
PCT/EP2008/063068 WO2009043844A2 (en) 2007-10-01 2008-09-30 Orodispersible tablets

Publications (1)

Publication Number Publication Date
BRPI0817927A2 true BRPI0817927A2 (pt) 2015-04-07

Family

ID=38962587

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817927-1A BRPI0817927A2 (pt) 2007-10-01 2008-09-30 Comprimidos orodispersiveis

Country Status (11)

Country Link
US (3) US9623010B2 (pt)
EP (2) EP2572705B1 (pt)
JP (1) JP2010540588A (pt)
KR (1) KR101626873B1 (pt)
BR (1) BRPI0817927A2 (pt)
CA (1) CA2703501C (pt)
ES (1) ES2645255T3 (pt)
PL (1) PL2572705T3 (pt)
PT (1) PT2572705T (pt)
WO (1) WO2009043844A2 (pt)
ZA (1) ZA201002255B (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
EP2151235B1 (de) * 2008-07-21 2011-02-16 Dr. Falk Pharma Gmbh Pharmazeutische Formulierung zur Behandlung des oberen Verdauungstraktes
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
CN102114014A (zh) * 2009-12-30 2011-07-06 北京德众万全药物技术开发有限公司 一种含有阿莫曲坦的药物组合物
US8906949B2 (en) * 2010-05-21 2014-12-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of zolmitriptan and process for preparing the same
FR2962331B1 (fr) * 2010-07-06 2020-04-24 Ethypharm Forme pharmaceutique pour lutter contre la soumission chimique, methode la mettant en oeuvre
WO2012014012A1 (es) * 2010-07-27 2012-02-02 Laboratorios Andrómaco S.A. Procedimiento para preparar comprimidos de disolucion rapida oral que comprenden la forma i de olanzapina, los comprimidos obtenidos y su uso para el tratamiento de la esquizofrenia.
KR102216603B1 (ko) 2010-08-04 2021-02-17 크레스토보 홀딩스 엘엘씨 분변 세균총 이식을 위한 조성물, 그의 제조 방법과 사용 방법, 및 그를 전달하기 위한 장치
KR101947720B1 (ko) 2010-12-13 2019-02-14 샐릭스 파마슈티컬스 인코포레이티드 위 및 결장 조제물 및 이의 제조 및 사용 방법
MX2013010343A (es) 2011-03-09 2014-04-30 Univ Minnesota Composicion y metodos para el transplante de microbiota de colon.
JP6208931B2 (ja) * 2011-09-07 2017-10-04 三菱商事フードテック株式会社 硬度を高めた口腔内崩壊錠およびその製造方法
WO2013095314A1 (en) * 2011-12-19 2013-06-27 Mahmut Bilgic Pharmaceutical formulations comprising risperidone
WO2013100876A1 (en) * 2011-12-27 2013-07-04 Mahmut Bilgic Risperidone formulations
WO2013172805A1 (en) * 2012-05-14 2013-11-21 Mahmut Bilgic New orodispersible tablet formulations of olanzapine
WO2013175508A2 (en) 2012-05-24 2013-11-28 Medreich Limited Stable pharmaceutical composition of aripiprazole
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
AU2013271336B2 (en) 2012-06-04 2017-11-30 Centre For Digestive Diseases Compositions and methods for treating Crohn's Disease and related conditions and infections
CA2880282C (en) 2012-07-27 2020-09-01 Redhill Biopharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation
US9101636B2 (en) 2012-11-30 2015-08-11 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
JP2016117651A (ja) * 2013-04-16 2016-06-30 株式会社ダイセル 小動物への投与に適した速崩壊錠とその簡便な製造方法
JP2016117652A (ja) * 2013-04-16 2016-06-30 株式会社ダイセル 小児への投与に適した速崩壊錠とその簡便な製造方法
US20160089363A1 (en) 2013-04-30 2016-03-31 Thomas Julius Borody Compositions and methods for treating microbiota-related psychotropic conditions and diseases
JP2014218472A (ja) * 2013-05-10 2014-11-20 エルメッド エーザイ株式会社 オランザピン乃至その塩含有錠剤
JP5713421B1 (ja) 2013-07-19 2015-05-07 株式会社三和化学研究所 口腔内崩壊錠
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
WO2015045604A1 (ja) * 2013-09-30 2015-04-02 富士フイルム株式会社 口腔内崩壊錠
WO2015067313A1 (en) * 2013-11-07 2015-05-14 Synthon B.V. Orodispersible pharmaceutical compositions comprising aripiprazole
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
ES2716990T5 (es) 2013-12-23 2023-03-24 Dr Falk Pharma Gmbh Formulación farmacéutica optimizada para el tratamiento de cambios inflamatorios del esófago
WO2015145461A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
CN114105851A (zh) 2014-07-02 2022-03-01 奥布赛瓦股份公司 治疗ot-r活性相关的病症的方法中可用的晶体
AU2015287186B2 (en) 2014-07-11 2018-05-31 Azanta Danmark A/S Misoprostol dispersible tablet
US20160008310A1 (en) 2014-07-11 2016-01-14 Azanta A/S Misoprostol dispersible tablet
WO2016183577A1 (en) 2015-05-14 2016-11-17 Crestovo Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
NZ737786A (en) 2015-05-22 2022-07-01 Univ Minnesota Methods for treating autism spectrum disorder and associated symptoms
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
WO2017053327A1 (en) 2015-09-24 2017-03-30 San Diego State University (Sdsu) Foundation , Dba San Diego State University Research Foundation Antibacterial and protective bacteriophage formulations and methods for making and using them
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
JP2020513018A (ja) 2017-04-05 2020-04-30 クレストヴォ・ホールディングス・エルエルシー パーキンソン病(pd)および関連する障害を治療するための組成物および方法
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
WO2018218159A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
JP2020530494A (ja) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド. 健康な腸バリアを維持及び回復するための組成物及び方法
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
AU2019351017A1 (en) 2018-09-27 2021-04-29 Finch Therapeutics Holdings Llc. Compositions and methods for treating epilepsy and related disorders
KR102084602B1 (ko) * 2018-11-08 2020-03-04 주식회사 서흥 발포성 및 안정성이 향상된 구강 세정용 발포정
CA3116354A1 (en) 2018-11-26 2020-06-04 The Procter & Gamble Company Solid pharmaceutical preparation containing lipoic acid and use thereof
EP3766483A1 (en) * 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
CN110477378B (zh) * 2019-08-02 2022-11-29 大连医诺生物股份有限公司 含脂溶性成分的口溶型直饮粉及其制备方法
CN112546002B (zh) * 2020-12-07 2022-08-05 北京斯利安药业有限公司 一种生物素口崩片及其制备方法
KR102413426B1 (ko) 2020-12-21 2022-06-29 주식회사 씨엠지제약 나라트립탄을 포함하는 구강용해 필름 제형
WO2024144678A1 (en) * 2022-12-27 2024-07-04 Atatürk Üni̇versi̇tesi̇ Fi̇kri̇ Mülki̇yet Haklari Koordi̇natörlüğü Döner Sermaye İşletmesi̇ Orally disintegrating tablets (odt) formulations for the treatment of flu, common cold and allergic symptoms

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6596311B1 (en) 1998-03-06 2003-07-22 Eurand International S.P.A. Fast disintegrating tablets
US20020071864A1 (en) * 1999-03-25 2002-06-13 Yuhan Corporation Rapidly disintegrable tablet for oral administration
US20030161879A1 (en) * 1999-06-29 2003-08-28 Shinji Ohmori Tablets quickly disintegrating in mouth
US20020076437A1 (en) 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
US6583722B2 (en) 2000-12-12 2003-06-24 Kimberly-Clark Worldwide, Inc. Wetness signaling device
US6610266B2 (en) 2001-11-28 2003-08-26 Michael C. Withiam Calcium metasilicates and methods for making
EP1488811A1 (en) 2002-03-06 2004-12-22 Kyowa Hakko Kogyo Co., Ltd. Tablets quickly disintegrating in oral cavity
US6984377B2 (en) * 2002-05-29 2006-01-10 J. M. Huber Corporation Oral care products comprising calcium metasilicates
ES2199061B1 (es) * 2002-06-10 2005-02-16 Laboratorios Vita, S.A. Comprimidos bucodispersables y procedimiento para su obtencion.
JP4726628B2 (ja) 2003-10-15 2011-07-20 富士化学工業株式会社 口腔内速崩壊性錠剤
US20050244347A1 (en) * 2004-04-30 2005-11-03 Mehra Dev K Oral care products comprising calcium phosphates
ES2255429B1 (es) * 2004-10-25 2007-08-16 Italfarmaco, S.A. Composiciones farmaceuticas bucodispersables.
EP1681048A1 (en) 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Orally disintegrating composition of olanzapine or donepezil
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
KR20140065482A (ko) * 2005-03-24 2014-05-29 다이이찌 산쿄 가부시키가이샤 의약용 조성물
JP4944467B2 (ja) * 2005-03-24 2012-05-30 第一三共株式会社 医薬用組成物
US20070202163A1 (en) * 2005-09-09 2007-08-30 Mutasem Rawas-Qalaji Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US20090208576A1 (en) 2006-03-31 2009-08-20 Gandhi Anilkumar S Orally Disintegrating Tablets
EP1977734A1 (en) * 2007-04-03 2008-10-08 Royal College of Surgeons in Ireland A method of producing fast dissolving tablets
WO2009038145A1 (ja) 2007-09-19 2009-03-26 Asahi Breweries, Ltd. 漢方エキス、生薬エキスあるいは天然物抽出エキスまたはそれらの混合物等の天然物由来物質を含有する顆粒物の製造方法およびその顆粒物から製造する錠剤の製造方法

Also Published As

Publication number Publication date
EP2572705A1 (en) 2013-03-27
KR20100077187A (ko) 2010-07-07
WO2009043844A2 (en) 2009-04-09
WO2009043844A3 (en) 2009-06-18
US20170157053A1 (en) 2017-06-08
PT2572705T (pt) 2017-11-08
ZA201002255B (en) 2011-12-28
PL2572705T3 (pl) 2018-01-31
US9623010B2 (en) 2017-04-18
JP2010540588A (ja) 2010-12-24
KR101626873B1 (ko) 2016-06-02
EP2205213A2 (en) 2010-07-14
CA2703501C (en) 2017-06-13
US20100297031A1 (en) 2010-11-25
CA2703501A1 (en) 2009-04-09
ES2645255T3 (es) 2017-12-04
EP2572705B1 (en) 2017-09-13
US20160310470A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
BRPI0817927A2 (pt) Comprimidos orodispersiveis
DK3090730T3 (da) Tabletter omfattende eltrombopag-olamin
BRPI0920521A2 (pt) combinação farmacêutica
BRPI0811269A2 (pt) Adoçante
ATE501136T1 (de) Imidazopyridinone
BRPI0810495A2 (pt) difenil-di-hidro-imidazopiridinonas
BRPI0808889A2 (pt) Comprimido desintegrante oral
BRPI0811451A2 (pt) Exopolissacarídeo
BRPI0814519A2 (pt) Organopolissiloxano
BRPI0812916A2 (pt) Chupeta
BRPI0812840A2 (pt) 2-imidazolinas
AT504327B8 (de) Tablettenabfüllvorrichtung
AT505058A3 (de) Türschliesssystem
DE112008001742A5 (de) Sensoranordnung
BRPI0812994A2 (pt) Microbiocidas
DK2272763T3 (da) Blisterpakning-dispensermaskine
DK2007384T3 (da) Orodispergerbare domperidontabletter
DE602007010950D1 (de) Dosierpumpe
DE112008000345A5 (de) Sensoranordnung
DE112008001216A5 (de) Magnetronplasmaanlage
CU20090155A7 (es) Macrolidos
DE102007038931A8 (de) Fadenlagennähwirkstoffe
ES1064046Y (es) Multiventuri dosificador
DK1970496T3 (da) Doseringsarrangement
DE112008001534A5 (de) Anreihgussform

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law
B06I Technical and formal requirements: publication cancelled
B07A Technical examination (opinion): publication of technical examination (opinion)
B09B Decision: refusal
B09B Decision: refusal

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL